Professor of Medicine, UC San Diego Moores Cancer Center
Oncology
Dr. Scott M. Lippman, MD
|
|
Give Review
Scott Lippman works in the field of Oncology. He graduated from Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a top medical college. Johns Hopkins University School of Medicine has a rank of 3 in research and a 29 in primary care He over the years received 3 awards: "Fellow (FASCO)", "Super Doctor" and "Whos Who in Medicine and Healthcare". Scott Lippman is a published MD. He published 102 publications, including: 'Effect of long-term vitamin E and selenium supplementation on urine F2-Isoprostanes, a biomarker of oxidative stress.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Cancer Prevention: Obstacles, Challenges and the Road Ahead.
- New DNA Methylation Markers and Global DNA Hypomethylation Are Associated with Oral Cancer Development.
- Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.
- Molecular Cancer prevention: Current status and future directions.
- Effect of Finasteride on Serum Androstenedione and Risk of Prostate Cancer Within the Prostate Cancer Prevention Trial: Differential Effect on High- and Low-grade Dise...
- Combined TP53 mutation/3p loss correlates with decreased radiosensitivity and increased matrix-metalloproteinase activity in head and neck Carcinoma.
- Matrix-metalloproteinases in head and neck carcinoma-Cancer genome atlas analysis and fluorescence imaging in mice.
- The ability of bilirubin in identifying smokers with higher risk of lung Cancer: a large cohort study in conjunction with global metabolomic profiling.
- Telomere length and recurrence risk after curative resection in patients with early-stage non-small cell lung Cancer: a prospective cohort study.
- Alterations Associated with Androgen Receptor Gene Activation in Salivary Duct Carcinoma (SDC) of Both Sexes: Potential Therapeutic Ramifications.
- Multi-tiered genomic analysis of head and neck Cancer ties TP53 mutation to 3p loss.
- Age-Related Cataract in Men in the Selenium and Vitamin E Cancer Prevention Trial Eye Endpoints Study: A Randomized Clinical Trial.
- Inflammation-related Genetic Variations and Survival for Advanced Non-Small Cell Lung Cancer Receiving First-line Chemotherapy.
- Increased leukocyte mitochondrial DNA copy number is associated with oral preMalignant lesions: an epidemiology study.
- An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.
- Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast Cancer.
- Prognostic Implications of Tumoral Expression of Insulin Like Growth Factors 1 and 2 in Patients With Non-Small-Cell Lung Cancer.
- Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin β3-Src Pathway.
- Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non-Small-Cell Lung Cancer:...
- Short telomere lengths in peripheral blood leukocytes are associated with an increased risk of oral preMalignant lesion and oral squamous cell carcinoma.
- Pathway-Based Serum microRNA Profiling and Survival in Patients with Advanced Stage Non-Small Cell Lung Cancer.
- Use of pharmacologic interventions for breast Cancer risk reduction: american society of clinical oncology clinical practice guideline.
- HER2-amplified salivary duct Carcinoma: Regression with dual HER2 inhibition and anti-VEGF combination treatment.
- Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial.
- Genome-wide association study of genetic predictors of overall survival for non-small cell lung Cancer in never smokers.
- Detailed Genome-Wide SNP Analysis of Major Salivary Carcinomas Localizes Subtype-Specific Chromosome Sites and Oncogenes of Potential Clinical Significance.
- Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE Lung trial.
- MicroRNA-Related Genetic Variants Associated with Clinical Outcomes in Early Stage Non-Small Cell Lung Cancer Patients.
- Three-dimensional mRNA measurements reveal minimal regional heterogeneity in esophageal squamous Cell carcinoma.
- An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhi...
- CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in Lung adenocarcinoma.
- Predictors of survival in never-smokers with non-small cell lung Cancer: a large-scale, two-phase genetic study.
- Epidermal growth factor receptor and K-Ras mutations and resistance of lung Cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.
- Natural-agent mechanisms and early-phase clinical development.
- Global evaluation of Eph receptors and ephrins in Lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
- Systematic Evaluation of Apoptotic Pathway Gene Polymorphisms and Lung Cancer Risk.
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome.
- Targeting the MAPK-RAS-RAF signaling pathway in Cancer therapy.
- An intermittent approach for Cancer chemoprevention.
- Aspirin and colorectal Cancer prevention in Lynch syndrome.
- Vitamin E and the risk of prostate Cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
- Akt/mammalian target of rapamycin counteract the antitumor activities of cixutumumab an anti-insulin-like growth factor I receptor monoclonal antibody.
- Novel Chromosomal Rearrangements and breakpoints at the t(6;9) in Salivary Adenoid Cystic Carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and cli...
- Common Genetic Variants in Cell Cycle Pathway Are Associated with Survival in Stage III-IV Non-Small Cell Lung Cancer.
- Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung Cancer.
- Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia: SWOG S9917.
- Repeat polymorphisms in estrogen metabolism genes and prostate Cancer risk: results from the Prostate Cancer Prevention Trial.
- Serum estrogen levels and prostate Cancer risk in the prostate Cancer prevention trial: a nested case-control study.
- Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events.
- Genetic variations in the transforming growth factor beta pathway as predictors of survival in advanced non-small cell lung Cancer.
- Genome-Wide Association Study of Survival in Non-Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy.
- Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected Lung nodules.
- Transition of a clinical trial into translational research: the prostate Cancer prevention trial experience.
- Prospective imaging assessment of mortality risk after head-and-neck radiotherapy.
- Budesonide versus placebo in high-risk population with screen-detected Lung nodules: rationale, design and methodology.
- Phase II study of dasatinib in patients with advanced non-small-cell lung Cancer.
- Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic Carcinoma: Incidence, variability, and clinicopathologic significance.
- Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemci...
- Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung Cancer and lung adenocarcinoma in mice.
- Profiling lipoxygenase metabolism in specific steps of colorectal tumorigenesis.
- Mortality in the randomized, controlled Lung intergroup trial of isotretinoin.
- Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell Cancer.
- Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung Cancer.
- Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung Cancer as frontline and second-line therapy.
- Unprecedented opportunities and promise for Cancer prevention research.
- Genetic variation in MicroRNA genes and risk of oral preMalignant lesions.
- Reduced DNA repair capacity for removing tobacco carcinogen-induced DNA adducts contributes to risk of head and neck Cancer but not tumor characteristics.
- Induction chemotherapy and cetuximab for locally advanced squamous Cell carcinoma of the head and neck: results from a phase II prospective trial.
- Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung Cancer.
- Elevated levels of urinary prostaGlandin e metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients.
- American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhib...
- DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral Cancer in patients with leukoplakia.
- Elevated epithelial insulin-like growth factor expression is a risk factor for lung Cancer development.
- Revisiting stage IIIB and IV non-small cell lung Cancer: analysis of the surveillance, epidemiology, and end results data.
- Selenium, genetic variation, and prostate Cancer risk: epidemiology reflects back on selenium and vitamin E Cancer prevention trial.
- Novel susceptibility loci for second primary tumors/recurrence in head and neck Cancer patients: large-scale evaluation of genetic variants.
- Cancer prevention: from 1727 to milestones of the past 100 years.
- Cancer prevention research: back to the future.
- Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck Cancer.
- Cyclooxygenase-2 gene polymorphisms reduce the risk of oral preMalignant lesions.
- Nutritional prevention of Cancer: new directions for an increasingly complex challenge.
- Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate Cancer.
- Algorithmic guided screening of drug combinations of arbitrary size for activity against Cancer cells.
- Phase I trial of weekly topotecan and gemcitabine in patients with solid Tumors.
- Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in Oral premalignancy.
- Effect of selenium and vitamin E on risk of prostate Cancer and other Cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
- High-dose fenretinide in Oral leukoplakia.
- Cyclin D1 and Cancer development in laryngeal premalignancy patients.
- Cancer Prevention Research. Letter from the Editor.
- The future of molecular-targeted Cancer chemoprevention.
- Genetic variations in cell-cycle pathway and the risk of oral preMalignant lesions.
- Gefitinib versus docetaxel in previously treated non-small-cell lung Cancer (INTEREST): a randomised phase III trial.
- Modulation of breast Cancer risk by nonsteroidal anti-inflammatory drugs.
- Lung Cancer.
- Cyclic AMP response element-binding protein overexpression: a feature associated with negative prognosis in never smokers with non-small cell lung Cancer.
- 15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation.
- Inaugural issue of Cancer Prevention Research.
- Epithelial to mesenchymal transition in head and neck squamous Carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggre...
- Does the level of prostate Cancer risk affect Cancer prevention with finasteride?
- Pilot randomized phase II study of celecoxib in oral preMalignant lesions.
- Effect of long-term vitamin E and selenium supplementation on urine F2-Isoprostanes, a biomarker of oxidative stress.
Schools
Johns Hopkins Univ Sch Of Med
Johns Hopkins Hospital
Harbor UCLA Med Center
Stanford Med Center
University Ariz Health Scis Center
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Breast Cancer
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Power Select HMO
- Blue Card PPO
- CaliforniaCare HMO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Pathway X Tiered Direct Access
- Select Plus HMO
- Great West Healthcare-Cigna PPO
- Commercial Insurance Company
- First Health (Coventry Health Care) PPO
- WholeCare Network HMO
- Humana
- Medicare MCR
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Options PPO
- United Healthcare
Awards
- Fellow (FASCO)
- Super Doctor
- Whos Who in Medicine and Healthcare
Education
-
University of Arizona -
Stanford University -
UCLA Affiliated Hospitals -
Harbor - UCLA Medical Center -
Johns Hopkins University School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center -
UC San Diego Health
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1780780874 |
| Last Name Of The Provider | LIPPMAN |
| First Name Of The Provider | SCOTT |
| View All |
Similar Doctors
|
|
Dr. Jennifer Atlas, MD |
|
|
Dr. John M. Carwile, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Mohsen Arani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hagop M. Kantarjian, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Jatin Shah, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria A. Zarzour, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Vinod K. Bhuchar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David J. Stewart, MD |
|
|
Dr. Eduardo D. Bruera, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aihua E. Yen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Munir Shahjahan, MD |
|
|
Dr. Perumal Thiagarajan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Apostolia M. Tsimberidou, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. George R. Elias, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jesus H. Hermosillo, MD |
|
|
Dr. Ibrahim F. Ibrahim, MD |
|
|
Dr. Xiaohong I. Wang, MD |